Renal cell carcinoma (RCC) is one of the most common genitourinary malignancies, accounting for about 3% of all cancers worldwide . With the improved imaging diagnostic technology, more RCC cases have been diagnosed at an early
stage. However, there is a considerable number of RCC patients at the time of diagnosis has been transferred . Research efforts have found various biomarkers of diagnostic and prognostic of RCC such as hypoxia-induced factor 1alpha (HIF1α), vascular endothelial growth factor (VEGF), and CX-5461 molecular weight carbonic GSK872 solubility dmso anhydrase IX (CA9), but they are not specific and sensitive enough to accurately predict the survival of RCC patients [19–21]. Recent studies indicate that epigenetic alterations play an important role in carcinogenesis, and global histone modifications as predictors of cancer recurrence in various tumor entities has begun to study. Patients with RCC have been found that total acetylation levels of histone H3 were inversely correlated with pT-stage, distant metastasis, Fuhrman Histone Methyltransferase inhibitor grading and RCC progression, whereas total histone H4Ac deacetylation was correlated with pT-stage and grading . All the above observations strongly suggest that histone modifications might be involved in the development and progression of RCC. However, it is not clear which
particular enzyme or specific modified lysine residue is responsible for tumorigenesis in RCC. This study aims to assess hMOF expression and its corresponding acetylation of histone H4K16 in the RCC via qRT-PCR, western blotting and immunohistochemistry. Simultaneously, Cobimetinib clinical trial we also investigated the correlation between the expression of hMOF and CA9. Materials and methods Materials Anti-H4K16 (Cat# H9164) polyclonal
antibody was purchased from Sigma. Anti-MYST1 (Cat# A300-992A) was obtained from Bethyl Laboratories. Anti-CA9 (Cat# sc-25599) was from Santa Cruz Biotechnology. Anti-GAPDH and anti-hMOF rabbit polyclonal antibodies were raised against bacterially expressed proteins (Jilin University). Tissue collection Human paired clinical RCC tissues and matched adjacent tissues were collected from patients with primary RCC between March 2011 and May 2012, who underwent kidney tumor radical surgery at the First Hospital of Jilin University. The study was approved by the Ethics Committee of the First Hospital of Jilin University and all patients gave informed consent. All removed tissues during the surgery were frozen immediately in liquid nitrogen and then stored at −80°C. Patient medical records including tumor staging, pathological diagnosis, and surgical records were reviewed. The pathologic diagnosis of the resected tumors was based on the American Joint Committee on Cancer . All patients did not receive chemotherapy or radiotherapy before surgery.